Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
| Revenue (TTM) | 937,000 |
| Gross Profit (TTM) | $-56.15M |
| EBITDA | $-89.27M |
| Operating Margin | -337686.00% |
| Return on Equity | -47.50% |
| Return on Assets | -28.00% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $4.17 |
| Price-to-Book | 1.49 |
| Price-to-Sales (TTM) | 445.37 |
| EV/Revenue | - |
| EV/EBITDA | -3.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -97.10% |
| Shares Outstanding | $55.72M |
| Float | $51.59M |
| % Insiders | 3.52% |
| % Institutions | 46.84% |
Volatility is currently expanding
The heavy selling pressure might have exhausted for Oculis Holding AG (OCS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZUG, Switzerland, November 3, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced results for the third quarter ended September 30, 2026, and provided an overview of the Company's progress.
Oculis Holding AG (OCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis' global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron Tansy, M.D.
Positive Phase 2 ACUITY trial findings support Privosegtor's potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum.
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OCS and any ticker you trade — then tracks every position and per-strategy win rate.
